Laboratory animal research · 2026
Application of exosomes derived from human umbilical cord stem cells in the treatment of ovalbumin-induced allergic asthma in mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ding Yong, Zhang Yanli, Cao Qi, Yin Yong, Ma Zhenglai, Pan Wenxia, Du Xinjie, Ma Chunling
Аннотация
BACKGROUND: This study investigated the therapeutic potential of exosomes derived from human umbilical cord mesenchymal stem cells (hUCMSCs-exos) in an Ovalbumin (OVA) -induced mouse model of allergic asthma, comparing their efficacy to budesonide, a standard asthma treatment. hUCMSCs-exos were characterized by their typical morphology, size, and marker expression (CD9, CD63, and HSP70) using transmission electron microscopy (TEM), Nanosight 300, and Western blot analysis.
RESULTS: Treatment with hUCMSCs-exos significantly decreased lung inflammation by detecting plasma IL-4 and IgE levels, as well as white blood cells and eosinophils counts in Bronchoalveolar lavage fluid (BALF), the M1 and M2 type of macrophages, Regulatory T Cells (Tregs) in lung tissues, paralleling the effects of budesonide therapy. Notably, hUCMSCs -exos achieved a greater reduction in the percentage of eosinophils in BALF and a significant increase M2 macrophages and Tregs in lung tissues.
CONCLUSIONS: These findings suggest hUCMSCs-exos may offer comparable or superior therapeutic benefits to budesonide, warranting further investigation into their molecular mechanisms to support clinical application.
RESULTS: Treatment with hUCMSCs-exos significantly decreased lung inflammation by detecting plasma IL-4 and IgE levels, as well as white blood cells and eosinophils counts in Bronchoalveolar lavage fluid (BALF), the M1 and M2 type of macrophages, Regulatory T Cells (Tregs) in lung tissues, paralleling the effects of budesonide therapy. Notably, hUCMSCs -exos achieved a greater reduction in the percentage of eosinophils in BALF and a significant increase M2 macrophages and Tregs in lung tissues.
CONCLUSIONS: These findings suggest hUCMSCs-exos may offer comparable or superior therapeutic benefits to budesonide, warranting further investigation into their molecular mechanisms to support clinical application.